Xeris Biopharma Holdings, Inc. (0A8E.L)

USD 3.29

(-4.76%)

Gross Profit Summary of Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.'s latest annual gross profit in 2024 was 135.26 Million USD , up 54.39% from previous year.
Xeris Biopharma Holdings, Inc.'s latest quarterly gross profit in 2024 FY was 124.42 Million USD , up 42.02% from previous quarter.
Xeris Biopharma Holdings, Inc. reported a annual gross profit of 87.61 Million USD in annual gross profit 2023, down 0.0% from previous year.
Xeris Biopharma Holdings, Inc. reported a annual gross profit of 87.61 Million USD in annual gross profit 2022, up 141.55% from previous year.
Xeris Biopharma Holdings, Inc. reported a quarterly gross profit of 124.42 Million USD for 2024 FY, up 42.02% from previous quarter.
Xeris Biopharma Holdings, Inc. reported a quarterly gross profit of 31.95 Million USD for 2024 Q3, down -6.31% from previous quarter.

Annual Gross Profit Chart of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Historical Annual Gross Profit of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Year	Gross Profit	Gross Profit Growth
2024	135.26 Million USD	54.39%
2023	87.61 Million USD	0.0%
2022	87.61 Million USD	141.55%
2021	36.27 Million USD	235.01%
2020	10.82 Million USD	346.84%
2019	2.42 Million USD	56.12%
2018	1.55 Million USD	45.45%
2017	1.06 Million USD	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q1	40.11 Million USD	31.74%
2024 FY	124.42 Million USD	42.02%
2024 Q3	31.95 Million USD	-6.31%
2024 Q4	37.56 Million USD	17.55%
2024 Q2	34.1 Million USD	-14.98%
2023 FY	87.61 Million USD	0.0%
2023 Q4	30.45 Million USD	9.24%
2023 Q3	27.87 Million USD	-8.46%
2023 Q2	30.45 Million USD	24.48%
2023 Q1	24.46 Million USD	19.36%
2022 Q2	16.54 Million USD	111.64%
2022 Q1	7.81 Million USD	41.5%
2022 FY	87.61 Million USD	141.55%
2022 Q4	20.49 Million USD	29.72%
2022 Q3	15.8 Million USD	-4.47%
2021 Q3	6.22 Million USD	69.07%
2021 Q2	3.68 Million USD	-44.35%
2021 FY	36.27 Million USD	235.01%
2021 Q1	6.61 Million USD	808.79%
2021 Q4	5.52 Million USD	-11.28%
2020 FY	10.82 Million USD	346.84%
2020 Q1	313 Thousand USD	5.39%
2020 Q4	728 Thousand USD	36500.0%
2020 Q3	-2000.00 USD	-100.77%
2020 Q2	261 Thousand USD	-16.61%
2019 Q2	759 Thousand USD	30.41%
2019 Q4	297 Thousand USD	19.76%
2019 FY	2.42 Million USD	56.12%
2019 Q1	582 Thousand USD	-28.94%
2019 Q3	248 Thousand USD	-67.33%
2018 Q2	467 Thousand USD	174.71%
2018 FY	1.55 Million USD	45.45%
2018 Q4	819 Thousand USD	270.59%
2018 Q3	221 Thousand USD	-52.68%
2018 Q1	170 Thousand USD	-69.7%
2017 Q3	354 Thousand USD	0.0%
2017 Q4	561 Thousand USD	58.47%
2017 FY	1.06 Million USD	0.0%

Peer Gross Profit Comparison of Xeris Biopharma Holdings, Inc.

Name	Gross Profit	Gross Profit Difference
Arrowhead Pharmaceuticals, Inc.	240.73 Million USD	43.81%
Codexis, Inc.	57.33 Million USD	-135.932%
Viridian Therapeutics, Inc.	-1 Million USD	13519.544%
Organovo Holdings, Inc.	-5.38 Million USD	2610.095%